Barts Health Nhs Trust

The NHS has approved enfortumab vedotin combined with pembrolizumab for bladder cancer patients, marking one of the most significant advances in decades for this difficult-to-treat disease.

Belzutifan showed a clinically meaningful 2.66-month improvement in quality-adjusted time without symptoms or toxicity (Q-TWiST) compared to everolimus in advanced renal cell carcinoma patients.

A retrospective analysis of 14 solar urticaria cases shows higher prevalence in women (57.14%), with rapid symptom onset within 15 minutes and resolution typically within 2 hours.

• UK researchers have developed Triple T (Targeted Thermal Therapy), a groundbreaking 20-minute minimally invasive procedure that treats primary aldosteronism without removing the adrenal gland. • The FABULAS trial demonstrated Triple T's safety and effectiveness in 28 patients, with most achieving normal hormone levels after six months and many discontinuing blood pressure medications. • This innovative treatment could potentially help millions worldwide, as primary aldosteronism affects 1 in 20 people with high blood pressure but is currently underdiagnosed and undertreated.

New research from the Stockholm Creatinine Measurements Project demonstrates that COVID-19 infection accelerates kidney function decline by 4.1 mL/min/1.73m2, significantly more than pneumonia.

Queen Mary University of London is leading a global trial testing a six-monthly injection as an alternative to daily blood pressure tablets for hypertension treatment.